Otelixizumab
- Generic Name
- Otelixizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 881191-44-2
- Unique Ingredient Identifier
- I5HF2X04PB
- Background
Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance and inhibit autoreactive disease activity. Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.
- Indication
Investigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
- Associated Conditions
- -
- Associated Therapies
- -
A Safety and Tolerability Study of Otelixizumab in Thyroid Eye Disease
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2020-10-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2
- Registration Number
- NCT01114503
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle upon Tyne, United Kingdom
Safety, Pharmacodynamics and Pharmacokinetics of GSK2136525 Repeat Dose in Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2010-03-01
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 12
- Registration Number
- NCT01077531
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle, Northumberland, United Kingdom
Subcutaneous Administration of Otelixizumab to T1DM Patients
- First Posted Date
- 2009-07-24
- Last Posted Date
- 2017-06-01
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 33
- Registration Number
- NCT00946257
- Locations
- 🇧🇪
GSK Investigational Site, Merksem, Belgium
TRX4 Monoclonal Antibody in Type 1 Diabetes (T1 DM)
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 88
- Registration Number
- NCT00451321
- Locations
- 🇨🇦
GSK Investigational Site, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.